Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Abstract PS3-10-05: Indications and Outcomes of Anthracycline-Based Regimens for Early-Stage Grade 3 Hormone Receptor-Positive Breast Cancer in a Real-World Scenario2026
2. 2Anthracycline- and taxane-containing chemotherapy for early-stage breast cancer2023
3. 3Abstract PS3-08-08: Anthracycline vs. Non-Anthracycline Chemotherapy Regimens for ER+/HER2− Early-Stage Breast Cancer Based on Oncotype DX Recurrence Score: A Retrospective Study2026
4. 4The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer—A Systematic Review and Meta-Analysis2024 · 8 citations
5. 5Annual report of national clinical database-breast cancer registry in 2023: systemic therapy for small breast cancer2026